NEW YORK – Biocytogen this week said it is partnering with Acepodia to advance a bispecific antibody-drug conjugate program to address unmet needs in solid tumors.
Within the partnership, Beijing-based Biocytogen will provide a bispecific antibody derived from its RenLite platform, which produces fully human bispecific antibodies with unique binding properties. Acepodia, which is headquartered in Alameda, California, will add two anti-cancer payloads to the antibody using bio-orthogonal click chemistry to create a conjugate with an optimal drug-to-antibody ratio for potency and safety.
Biocytogen said in an email that drug candidates resulting from its partnership with Acepodia will be developed for biomarker-defined patient populations.
"This partnership redefines the possibilities of ADC design, with the potential to deliver breakthrough therapies to patients in desperate need of new options," Biocytogen CEO Yuelei Shen said in a statement.
Biocytogen licensed a preclinical B7H3/PTK7 bispecific antibody to Ideaya in November 2024 and partnered with Guangzhou FineImmune Biotechnology in September 2022 to develop antibody-based cell therapies targeting intracellular tumor-associated antigens.